ERBB2 and metastatic neoplasm: Twenty-six patients (22.6%) with HER2-low breast cancer received T-DXd after SG therapy (among these, four patients had HER2 IHC zero at the time of biopsy of the metastatic disease site but were observed to have HER2-low disease during the initial diagnosis of breast cancer).